156 related articles for article (PubMed ID: 21327440)
1. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
Iwasa S; Yamada Y; Fukagawa T; Eguchi Nakajima T; Kato K; Hamaguchi T; Morita S; Saka M; Katai H; Shimada Y
Gastric Cancer; 2011 Mar; 14(1):28-34. PubMed ID: 21327440
[TBL] [Abstract][Full Text] [Related]
2. Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer.
Kim SJ; Kim YJ; Kim JH; Park DJ; Kim HH; Lee JS; Lee KW
Cancer Sci; 2013 Jan; 104(1):116-23. PubMed ID: 23066919
[TBL] [Abstract][Full Text] [Related]
3. Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer.
Hirahara N; Matsubara T; Kaji S; Yamamoto T; Hyakudomi R; Takai K; Ishitobi K; Uchida Y; Tajima Y
BMC Cancer; 2021 Oct; 21(1):1073. PubMed ID: 34598694
[TBL] [Abstract][Full Text] [Related]
4. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
7. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment.
Chou WC; Chang CL; Liu KH; Hsu JT; Cheng WH; Hsu HC; Shen WC; Hung YS; Chen JS
World J Surg Oncol; 2013 Nov; 11():287. PubMed ID: 24180462
[TBL] [Abstract][Full Text] [Related]
8. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.
Yoshimura K; Uehara K; Tojima Y; Kawai S; Mokuno Y; Maeda A; Kyokane T; Kobayashi S; Yoshioka Y; Nagino M
Trials; 2013 Jan; 14():17. PubMed ID: 23320901
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
10. Alternate-day treatment with S-1 in patients with gastric cancer: a retrospective study of strategies for reducing toxicity.
Sakuma K; Hosoya Y; Arai W; Haruta H; Ui T; Kurashina K; Saito S; Hirashima Y; Yokoyama T; Zuiki T; Hyodo M; Nagai H; Yasuda Y; Shirasaka T
Int J Clin Oncol; 2010 Apr; 15(2):166-71. PubMed ID: 20195683
[TBL] [Abstract][Full Text] [Related]
11. [Examination of the feasibility of TS-1 for postoperative advance stomach cancer patients].
Hara A; Tokuhara T; Takahashi Y; Izumi N; Iwamoto S; Satake K
Gan To Kagaku Ryoho; 2004 Apr; 31(4):601-4. PubMed ID: 15114708
[TBL] [Abstract][Full Text] [Related]
12. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer.
Tsujitani S; Fukuda K; Kaibara N
Gastric Cancer; 2003; 6 Suppl 1():50-7. PubMed ID: 12775021
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703).
Kodera Y; Ishiyama A; Yoshikawa T; Kinoshita T; Ito S; Yokoyama H; Mochizuki Y; Ito H; Tsuburaya A; Sakamoto J; Nakao A;
Gastric Cancer; 2010 Aug; 13(3):197-203. PubMed ID: 20820990
[TBL] [Abstract][Full Text] [Related]
16. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
17. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
18. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Yoshikawa T; Terashima M; Mizusawa J; Nunobe S; Nishida Y; Yamada T; Kaji M; Fukushima N; Hato S; Choda Y; Yabusaki H; Yoshida K; Ito S; Takeno A; Yasuda T; Kawachi Y; Katayama H; Fukuda H; Boku N; Sano T; Sasako M
Lancet Gastroenterol Hepatol; 2019 Mar; 4(3):208-216. PubMed ID: 30679107
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
20. [A case of CA19-9 producing gastric cancer treated by low-dose administration of TS-1 for adjuvant chemotherapy].
Takashima I; Seto Y; Nagamine I; Kegoya Y; Kodoi A; Nakayama H
Gan To Kagaku Ryoho; 2005 Apr; 32(4):503-5. PubMed ID: 15853217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]